# OnCo record ak117 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ak117/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ak117" ;
  schema:name "AK117"@en ;
  schema:description "AK117 is an experimental investigational agent whose form is not stated in the registry from Akeso in phase 3 trials for head and neck squamous cell carcinoma, colorectal cancer and non-small-cell lung cancer, with its target not yet stated publicly."@en ;
  schema:url <https://onco.cc/drugs/ak117/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=AK117>, <https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ligufalimab>, <https://clinicaltrials.gov/study/NCT04980885> ;
  onco:status "phase-3" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "monoclonal antibody (AK117 is ligufalimab; INN stem -mab; form not stated in the registry record)" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/sclc/> ;
  onco:targets <https://onco.cc/targets/cd47/> ;
  onco:companies <https://onco.cc/companies/akeso/> ;
  onco:trials <https://onco.cc/trials/nct06601335/>, <https://onco.cc/trials/nct07245446/>, <https://onco.cc/trials/nct05382442/>, <https://onco.cc/trials/nct05229497/>, <https://onco.cc/trials/nct05227664/>, <https://onco.cc/trials/nct04980885/> .